多种疗法达到二次预防的LDL-C目标在LDL-受体零同位素家族高胆固醇血症
Areej Alkhairy1, Pinhao Xiang2, John K Khoo3
1Division of Endocrinology and Metabolism, University of British Columbia, Vancouver, Canada; Division of Endocrinology and Metabolism, King Faisal Specialist Hospital and Research Centre, Jeddah, Saudi Arabia.
JACC. Case reports
|August 22, 2025
概括
同胞性家族性高胆固醇血症 (HoFH) 需要积极的多模式治疗. 组合治疗可以显著降低低密度脂蛋白胆固醇 (LDL- C) 并预防儿童心血管疾病的进展.
科学领域:
- 遗传学
- 心脏病学
- 药理学
背景情况:
- 同卵性家族高胆固醇血症 (HoFH) 是一种罕见的严重遗传性疾病.
- 它主要是由LDLR基因的致病变体引起的.
- 没有治疗的HoFH会导致过早死亡,通常在20岁之前.
研究的目的:
- 报告一个严重的HoFH儿童病例.
- 评估HoFH综合多模式治疗策略的有效性.
- 评估治疗对心血管疾病进展的影响.
主要方法:
- 一名患有高FH和极高LDL- C水平的4岁男孩接受了治疗.
- 基因分析证实了具有最小残留活性的双性LDLR变体 (LDLR-null).
- 治疗包括最大剂量罗斯瓦斯他林,埃泽蒂米布,血交换,洛米塔皮德和埃维纳库马布.
主要成果:
- 组合治疗达到指导方针建议的LDL- C水平 (< 70 mg/ dL).
- 在治疗期间没有观察到过早冠心病的进展.
- 这种多模式的方法使得以前无法实现的LDL-C降低.
结论:
- 有效的HoFH管理需要密集的多模式降脂疗法.
- 目前的治疗方法可以显著降低LDL-C并预防血管并发症.
- 激烈降低LDL- C可能会避免对HoFH患者进行肝移植.
相关概念视频
Atherosclerosis III: Management
33
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
33
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
869
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
869
Coronary Artery Disease IV: Preventive Measures
32
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
32
Atherosclerosis IV: Nursing Management
50
Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
50
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
38
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
38
Hypertension IV: Drug Therapy and Lifestyle Modifications
38
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
38


